Factor V Leiden is the most common inherited blood-clotting disorder, caused by a single genetic change in the gene for clotting factor V that makes the protein resistant to one of the body’s natural anticoagulant systems. Roughly one in twenty people of European descent carries a copy of the mutation, yet the vast majority never develop a blood clot. That gap between how common the mutation is and how rarely it causes problems defines almost every clinical decision around it, from whether to test for it to how aggressively to treat it.
What the Mutation Actually Does
Your blood has a built-in braking system for clotting. When a clot forms, a protein called activated protein C (APC) normally latches onto clotting factor V and switches it off, keeping the clot from growing out of control. In people with Factor V Leiden, a single amino acid swap in the factor V protein prevents APC from shutting it down efficiently.1PubMed. Activated protein C resistance and factor V Leiden: a review The result is factor V that stays active longer than it should, nudging the clotting balance toward forming clots more easily. This is sometimes called “APC resistance,” and it is the hallmark lab finding associated with the mutation.
Carrying one copy of the mutated gene (heterozygous) leaves you with a modest tilt toward clotting. Carrying two copies (homozygous) amplifies the effect considerably, because neither copy of your factor V responds normally to APC. Most of the clinical discussion focuses on heterozygous carriers, since they vastly outnumber homozygous ones.
How Common It Is and Who Carries It
Factor V Leiden is overwhelmingly a mutation found in people of European ancestry. In a large study of over 4,000 Americans, the carrier rate among white Americans was about 5%, compared with roughly 2% in Hispanic Americans, about 1% in African Americans and Native Americans, and under half a percent in Asian Americans.2PubMed. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening A separate study of patients on long-term blood thinners found an even higher heterozygous rate among European Americans at about 9%, versus roughly 1.4% among African Americans.3PubMed Central. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
Within Europe itself, the mutation is not evenly distributed. An analysis of nearly 6,000 individuals from 26 European populations found a mean allele frequency of about 2.7%, with a striking peak above 12% in Cyprus. The mutation was absent in Inuit populations and very rare among French Basques. Geographically, prevalence generally increased from west to east across the continent.4PubMed. Population genetics of factor V Leiden in Europe This uneven distribution has fueled longstanding speculation about an evolutionary advantage, which we will return to later.
The Actual Risk of Getting a Blood Clot
The phrase “increased clotting risk” can sound alarming, but the absolute numbers tell a calmer story for most carriers. A prospective study that followed asymptomatic carriers over time found that the annual rate of spontaneous venous thromboembolism (VTE) was low enough that the researchers concluded routine screening of family members was not justified.5PubMed. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism In a large family cohort, heterozygous carriers had an annual deep vein thrombosis (DVT) rate of about 0.41%, compared with 0.19% in non-carriers, roughly double the risk in relative terms. When other inherited clotting conditions were excluded, the relative risk climbed to about seven-fold for DVT specifically.6PubMed Central. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects
An interesting wrinkle is the so-called “Factor V Leiden paradox”: the mutation raises the risk of DVT in the legs more clearly than it raises the risk of pulmonary embolism. In that same family study, the annual rate of pulmonary embolism was nearly identical in carriers and non-carriers, about 0.07% for both groups.6PubMed Central. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects Researchers are still debating why this is the case. One theory is that clots in Factor V Leiden carriers may be more stable and less likely to break off and travel to the lungs, but this remains unproven.
Meta-analyses pooling data from many studies have estimated the odds ratio for VTE in heterozygous carriers at roughly four to five times that of non-carriers.7Thrombosis and Haemostasis. Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism Homozygous carriers face a markedly higher risk, with some estimates around eleven-fold.8PubMed Central. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T Still, because the baseline risk of VTE in a healthy young person is already very low, even a five-fold or eleven-fold increase translates to a small absolute number.
Symptoms to Watch For
Factor V Leiden itself does not cause daily symptoms. You can carry the mutation your entire life and never know it. The symptoms that matter are the symptoms of a blood clot, which can appear at any age but often strike during a period of added risk: after surgery, during pregnancy, while on hormonal birth control, or after prolonged immobility like a long flight or hospital stay.
The most common clot presentation is a DVT, usually in a leg. Signs include swelling in one leg, pain or tenderness (often starting in the calf), warmth, and redness or discoloration. If a clot travels to the lungs (pulmonary embolism), you may experience sudden shortness of breath, chest pain that worsens with breathing, a rapid heartbeat, or coughing up blood. This is a medical emergency.
Less commonly, Factor V Leiden has been linked to clots in unusual locations. One study found the mutation in about 21% of patients with cerebral venous thrombosis (clots in the veins draining the brain), compared with only 2% of controls.9PubMed. Factor V Leiden mutation in cerebral venous thrombosis In most of those patients, an additional trigger like oral contraceptive use or recent childbirth was also present, underscoring that Factor V Leiden rarely acts alone.
Oral Contraceptives and Hormone Therapy
This is where Factor V Leiden becomes a genuinely dangerous combination. Estrogen-containing oral contraceptives raise clotting risk on their own, and in carriers of the mutation, the risks multiply rather than simply add up. A landmark study in The Lancet found that women who both used oral contraceptives and carried Factor V Leiden had a roughly 35-fold increased risk of venous thrombosis compared with women who had neither risk factor.10PubMed. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
The type of progestin in the pill matters, too. Newer-generation progestins like desogestrel and gestodene appear to carry higher combined risks than older formulations containing levonorgestrel. One study estimated that carriers of Factor V Leiden using a desogestrel-containing pill faced a nearly 50-fold increase in thrombosis risk compared with non-carrier non-users.11The Lancet. Effect of lower-dose oral contraceptives on venous thromboembolism with particular reference to the desogestrel-containing contraceptives A more recent analysis confirmed that desogestrel and cyproterone acetate formulations carried the highest joint risk estimates with genetic thrombophilia, while levonorgestrel-based pills had the lowest combined risk among the types studied.12PubMed Central. The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
These numbers sound dramatic, and they are in relative terms. But context matters: the baseline annual risk of VTE in a young woman not on the pill is extremely low (roughly 1-2 per 10,000 per year). A 35-fold increase pushes that to roughly 3-7 per 1,000 per year. That is high enough to take seriously, but it means most carriers on the pill still will not develop a clot in any given year. The clinical takeaway is that if you know you carry Factor V Leiden, progestin-only methods or non-hormonal contraception are strongly preferred. Testing before prescribing hormonal contraception is debated, which brings us to the thorny topic of when testing even makes sense.
Pregnancy and Factor V Leiden
Pregnancy is itself a hypercoagulable state; the body ramps up clotting factors to prepare for the bleeding of delivery. Adding Factor V Leiden on top of that can raise the risk of both blood clots and certain pregnancy complications. A systematic review and meta-analysis of prospective studies found that women carrying the mutation had about a 52% higher odds of pregnancy loss compared with non-carriers, with absolute risks of roughly 4.2% versus 3.2%.13PLoS Medicine. The Association of Factor V Leiden and Prothrombin Gene Mutation and Placenta-Mediated Pregnancy Complications: A Systematic Review and Meta-analysis of Prospective Cohort Studies That same analysis found no significant link between the mutation and pre-eclampsia or growth restriction.
Other research has pointed to associations with more severe placental problems, including early-onset gestational hypertension, HELLP syndrome, placental abruption, stillbirth, and placental infarction.14PubMed Central. The effect of factor V Leiden carriage on maternal and fetal health The discrepancies between studies likely reflect differences in how “pregnancy complications” are defined and which stages of pregnancy are examined. First-trimester miscarriage, for example, has a weaker and less consistent link to the mutation than later losses.
For carriers with a history of pregnancy complications, low-molecular-weight heparin (LMWH) injections during pregnancy appear to help. One study of carriers of Factor V Leiden or the prothrombin mutation found that LMWH roughly halved the odds of miscarriage and dramatically reduced pregnancy-related VTE. Among women who had already experienced two or more pregnancy complications, the highest rate of live births occurred in the group receiving LMWH.15PubMed. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation Aspirin alone did not show a comparable benefit in that study. The American College of Obstetricians and Gynecologists (ACOG) has published guidance on managing inherited thrombophilias in pregnancy, including recommendations on which carriers warrant prophylactic blood thinners and which do not.16PubMed. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy
How It Is Diagnosed
There are two main approaches. The first is a functional blood test that measures APC resistance directly: your blood sample is tested with and without added activated protein C, and the ratio of clotting times tells the lab whether your factor V responds normally. Modern versions of this test, using a dilute Russell viper venom reagent, achieve sensitivity and specificity above 99%.17American Journal of Clinical Pathology. An Improved Algorithm for Activated Protein C Resistance and Factor V Leiden Screening A newer factor V-depleted plasma assay further reduced the number of equivocal results that need follow-up genetic testing.18American Journal of Clinical Pathology. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden
The second approach is a DNA-based genetic test that looks directly for the specific mutation. This is definitive: it tells you not just that APC resistance is present, but that it is caused by Factor V Leiden rather than some other reason (like liver disease or lupus anticoagulant, which can also cause APC resistance). The DNA test also distinguishes heterozygous from homozygous carriers, which matters for risk assessment and management decisions. In practice, many labs use the functional test as a screen and confirm positive or borderline results with genetic testing.
When Testing Does and Does Not Make Sense
This is one of the most contentious areas in clinical practice. An influential evaluation by the EGAPP Working Group recommended against routine Factor V Leiden testing in two situations: adults who have already had an unexplained VTE, and asymptomatic family members of known carriers.19Genetics in Medicine. Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members The reasoning is practical: for someone who already had a clot, the decision about how long to stay on blood thinners depends on clinical factors (was the clot provoked or unprovoked, how high is the bleeding risk) more than on whether they carry the mutation. And for asymptomatic relatives, knowing they carry the mutation rarely changes management enough to outweigh the potential harms of testing, including unnecessary anxiety, insurance complications, and overtreatment.
Where testing is more clearly useful is in guiding contraceptive choices for women with a strong family history of clotting, and in managing pregnant women who have had recurrent pregnancy losses or VTE. In these situations, confirming the mutation can directly influence which medications or contraceptive methods are recommended.
Treatment After a Clot
If you carry Factor V Leiden and develop a VTE, the acute treatment is anticoagulation, the same as for anyone else with a blood clot. The question is which drug and for how long. Traditionally, treatment started with heparin injections bridged to warfarin. Direct oral anticoagulants (DOACs) like rivaroxaban and apixaban have increasingly replaced this approach, and evidence suggests they work well in carriers of inherited clotting disorders. A prospective cohort study found that DOACs and heparin/warfarin had similar rates of recurrent clots during treatment, and that DOAC users actually had a lower two-year recurrence rate after stopping the medication.20PubMed Central. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study Even in the higher-risk group of homozygous carriers, a study comparing DOACs to warfarin found no significant difference in recurrence or major bleeding rates.21PubMed. Efficacy and safety of anti-Xa direct oral anticoagulants vs. warfarin in patients homozygous for Factor V Leiden and prothrombin G20210A mutations
The trickier question is duration. A decision analysis found that for heterozygous carriers, lifetime anticoagulation was favored over short-term treatment under most realistic assumptions about recurrence and bleeding risk.22Thrombosis Research. Anticoagulation duration in heterozygous factor V Leiden: A decision analysis In practice, though, the decision is individualized. A first clot that was clearly provoked by surgery or immobilization may warrant only three to six months of treatment, while an unprovoked clot, especially in a homozygous carrier or someone with additional risk factors, often leads to extended or indefinite anticoagulation.
When Other Risk Factors Stack Up
Factor V Leiden almost never acts in isolation. Most carriers who develop a clot have at least one additional trigger. Major surgery is a potent one: one study found that patients with Factor V Leiden who underwent orthopedic surgery had roughly a 17.5-fold increased odds of VTE compared with patients without the mutation who were not having surgery.23PubMed. High risk of venous thromboembolism after orthopedic surgery in patients with thrombophilia Other well-known stacking risks include obesity, cancer, immobility, long-haul travel, and older age.
Genetic stacking matters too. Carrying both Factor V Leiden and the prothrombin 20210A mutation (another common inherited thrombophilia) raises VTE risk above either mutation alone, though a large meta-analysis found the combined risk in double heterozygotes was lower than previously thought, at about a three-and-a-half-fold increase rather than the multiplicative estimates sometimes cited.8PubMed Central. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T The MTHFR C677T variant, despite lingering popular concern, showed no significant independent association with VTE in that same analysis.
Does Factor V Leiden Cause Heart Attacks and Strokes?
This distinction is important: Factor V Leiden is primarily a risk factor for venous clots, not arterial ones. Arterial events like heart attacks and most strokes are driven by atherosclerosis and platelet-rich clots, a different biological process from the fibrin-heavy clots in veins. A study of young adults found no association between Factor V Leiden and ischemic stroke.24PubMed Central. FACTOR V LEIDEN AND ISCHEMIC STROKE RISK: THE GENETICS OF EARLY ONSET STROKE (GEOS) STUDY A meta-analysis did find a modest roughly two-fold association in young adults, but it was heavily influenced by studies that specifically selected patients suspected of having a clotting disorder; in unselected stroke populations, the link was weak and not statistically significant.25PubMed Central. Meta-analysis of factor V Leiden and ischemic stroke in young adults: the importance of case ascertainment The upshot: if you carry Factor V Leiden, your heart and brain artery risk is governed by the usual suspects (blood pressure, cholesterol, smoking, diabetes), not by the mutation.
Factor V Leiden in Children
Blood clots in children are rare but do happen, and Factor V Leiden is one of the most commonly identified genetic risk factors when they do. A study of 85 pediatric patients with thromboembolic events found about 14% carried the mutation. Among neonates with arterial strokes in the brain, the rate was even higher at 27%.26PubMed. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease Almost universally, though, the affected children had at least one additional risk factor: infection was the most common trigger, and some had other underlying conditions like connective tissue disorders.27PubMed. Clinical manifestations in thrombotic children with factor V Leiden mutation The two homozygous children in that series developed a severe condition called purpura fulminans, resulting in limb amputations. This extreme outcome is exceedingly rare and essentially confined to homozygous carriers in the newborn period.
Why the Mutation Is So Common in the First Place
A mutation that raises clotting risk might seem like something natural selection would weed out. The fact that Factor V Leiden remains at carrier frequencies of 5% or higher in many European populations suggests it has historically conferred some survival advantage. The leading theory centers on hemorrhage: in an era before modern obstetrics and surgery, slightly faster clotting could reduce the risk of fatal bleeding during childbirth, trauma, or menstruation. Carriers have been reported to experience less blood loss during delivery and to have higher hemoglobin levels.28PubMed. Carriership of Factor V Leiden and evolutionary selection advantage
The list of potential advantages is surprisingly long: lower risk of intracranial hemorrhage, milder symptoms in hemophilia carriers, higher survival in severe sepsis, better outcomes in acute respiratory distress syndrome, and even higher fertility in both men and women.29PubMed. Evolution of Factor V Leiden None of these individual findings clinch the argument, but together they paint a picture of a mutation that, in pre-modern conditions, may have saved more lives through reduced bleeding and infection resistance than it cost through clotting. In today’s world of sedentary lifestyles, hormonal contraceptives, and longer life spans, the balance has shifted, and the clotting downside is what we notice.
The Psychological Side of a Positive Test
Learning you carry a genetic clotting mutation can be psychologically complicated, especially when the medical advice is often “you probably don’t need treatment.” A systematic review of the psychological impact of thrombophilia testing found that most people (around 88-94%) were ultimately glad to know their status. At the same time, a substantial minority, roughly 27-43% depending on the study, reported increased worry after testing.30Journal of Thrombosis and Haemostasis. The psychological impact of testing for thrombophilia: a systematic review Qualitative research has documented that asymptomatic carriers sometimes experience daily anxiety, feel stigmatized, and encounter problems with insurance eligibility.
A separate survey of people with Factor V Leiden confirmed the paradox: 88% were glad to know their genetic results, but 43% reported being more worried as a consequence.31PubMed. Knowledge and educational needs of individuals with the factor V Leiden mutation Many participants also had significant knowledge gaps about what the mutation actually meant for their health. This underscores the importance of genetic counseling alongside testing, something that is often missing when testing is ordered without a clear clinical indication. If you are considering being tested, it helps to think in advance about what you would do differently with the information, because for many asymptomatic carriers, the honest answer is “not much.”